Design Therapeutics Inc

1
NAS:DSGN (USA)  
$ 3.38 +0.07 (+2.11%) 11:08 PM EST
At Loss
P/B:
0.71
Market Cap:
$ 190.95M
Enterprise V:
$ -76.86M
Volume:
130.75K
Avg Vol (2M):
229.63K
Trade In:
Volume:
130.75K
At Loss
Avg Vol (2M):
229.63K

Business Description

Description
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 94.05
Equity-to-Asset 0.97
Debt-to-Equity 0.01
Debt-to-EBITDA -0.04
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -107.6
3-Year EPS without NRI Growth Rate -97.7
3-Year FCF Growth Rate -86.5
Name Current Vs Industry Vs History
5-Day RSI 28.26
9-Day RSI 31.93
14-Day RSI 36.23
6-1 Month Momentum % 62.99
12-1 Month Momentum % -24.73

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 38.61
Quick Ratio 38.61
Cash Ratio 38.16

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.6
Shareholder Yield % 0.33
Name Current Vs Industry Vs History
ROE % -20.35
ROA % -19.5
ROIC % -796.35
ROC (Joel Greenblatt) % -1448.27
ROCE % -24.39

Financials (Next Earnings Date:2024-08-14 Est.)

DSGN's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:DSGN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Design Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.05
Beta 1.96
Volatility % 100.03
14-Day RSI 36.23
14-Day ATR ($) 0.217451
20-Day SMA ($) 3.868
12-1 Month Momentum % -24.73
52-Week Range ($) 1.94 - 8.31
Shares Outstanding (Mil) 56.5

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Design Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Design Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Design Therapeutics Inc Frequently Asked Questions

What is Design Therapeutics Inc(DSGN)'s stock price today?
The current price of DSGN is $3.38. The 52 week high of DSGN is $8.31 and 52 week low is $1.94.
When is next earnings date of Design Therapeutics Inc(DSGN)?
The next earnings date of Design Therapeutics Inc(DSGN) is 2024-08-14 Est..
Does Design Therapeutics Inc(DSGN) pay dividends? If so, how much?
Design Therapeutics Inc(DSGN) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1